4-Aminoisoxazolidin-3-one
Common Name: |
4-Aminoisoxazolidin-3-one |
IUPAC Name: |
4-amino-1,2-oxazolidin-3-one |
Molecular Formula: |
C3H6N2O2 |
SMILES: |
C1C(C(=O)NO1)N |
Inchi: |
1S/C3H6N2O2/c4-2-1-7-5-3(2)6/h2H,1,4H2,(H,5,6) |
Inchi Key: |
DYDCUQKUCUHJBH-UHFFFAOYSA-N |
Cas No: |
68-39-3 |
Name |
Value |
Lipinski Violations |
0 |
Ghose Violations |
4 |
Veber Violations |
0 |
Egan Violations |
0 |
Muegge Violations |
2 |
Name |
Value |
Molecular Weight (g/mol) |
102.09 |
Mass (g/mol) |
102.043 |
Molar Refractivity |
25.13 |
Net Charge |
|
HBD |
2 |
HBA |
3 |
Rt Bonds |
0 |
Rings |
1 |
TPSA |
64.35 |
Hetero Atoms |
4 |
Heavy Atoms |
7 |
Aromatic Heavy Atoms |
0 |
Melting Point (°C) |
155.00 |
Boiling Point (°C@760.00mm Hg) |
|
Vapor Pressure (mmHg@25.00 °C) |
|
Vapor Density (Air =1) |
|
Fraction Csp3 |
0.67 |
LogP |
-0.785 |
iLOGP |
0.53 |
XLOGP3 |
-1.51 |
WLOGP |
-2.01 |
MLOGP |
-1.68 |
ESOL Log S |
0.48 |
ESOL Solubility (mg/ml) |
307 |
ESOL Solubility (mol/l) |
3.01 |
ESOL Class: esol_class |
Highly soluble |
Ali Log S |
0.66 |
Ali Solubility (mg/ml) |
471 |
Ali Solubility (mol/l) |
4.62 |
Ali Class |
Highly soluble |
Silicos-IT LogSw |
0.27 |
Silicos-IT Solubility (mg/ml) |
192 |
Silicos-IT Solubility (mol/l) |
1.88 |
Silicos-IT Class |
Soluble |
Name |
Value |
GI Absorption |
Low |
BBB Permeable |
0 |
PgP Substrate |
0 |
Log Kp (cm/s) |
-7.99 |
Bioavailability Score |
0.55 |
Caco2 |
0 |
Human Intestinal Absorption |
1 |
Plasm Protein Binding |
0.16 |
CYP1A2 Inhibitor |
0 |
CYP2C19 Inhibitor |
0 |
CYP2C9 Inhibitor |
0 |
CYP2D6 inhibitor |
0 |
CYP3A4 inhibitor |
0 |
Ames mutagenesis |
1 |
Acute Oral Toxicity |
1.269 |
Carcinogenicity (Binary) |
0 |
Carcinogenicity (Trinary) |
Non-required |
Eye Irritation |
0 |
Hepatotoxicity |
0 |
Androgen Receptor Binding |
0 |
Aromatase Binding |
0 |
Estrogen Receptor Binding |
0 |
Glucocorticoid Receptor Binding |
0 |
Thyroid Receptor Binding |
0 |
BRCP inhibitor |
0 |
BSEP inhibitor |
0 |
OATP1B1 inhibitor |
1 |
OATP1B3 inhibitor |
1 |
OATP2B1 inhibitor |
0 |
OCT1 inhibitor |
0 |
OCT2 inhibitor |
0 |